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Pre-treatment HIV drug resistance (PDR) is increasing in sub-Saharan Africa (SSA), driven by 
increasing resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs1. This has led 
the WHO to recommend that countries with a population prevalence of NNRTIs resistance >10% 
adopt alternate first-line regimens, or consider pre-therapy drug resistance testing to guide selection of 
antiretroviral therapy (ART)1,2. In response, many countries in SSA are now rolling out dolutegravir-
based first-line ART. These recommendations rely on the theoretical basis that efavirenz (EFV) 
efficacy is significantly curtailed in the presence of NNRTI resistance and that drug resistance testing 
prior to initiation of EFV-based ART enables selection of more efficacious regimens, respectively. 
Yet, for these theories to be true and support guideline changes, various criteria must be met: 1) EFV 
efficacy must be significantly reduced in the face of circulating NNRTI resistance; 2) PDR must be of 
sufficient prevalence that testing for it will have population-level effects on viral suppression and 3) 
pre-treatment drug resistance testing for selection of optimal regimens will improve outcomes. Yet, 
clinical data in support of these theories are either contradicting or altogether lacking. 
In this issue of Lancet HIV, Chung and colleagues3 attempt to resolve the latter two of these criteria 
by evaluating whether using an oligonucleotide assay (OLA) to detect genotypic drug resistance to 
NNRTIs at codons K103N, Y181C, G190A, and to lamivudine at M184V, could improve virologic 
suppression after initiation of NNRTI-based ART in Kenya. The investigators randomized 991 
participants to either standard of care without pre-ART resistance testing or use of the OLA assay to 
tailor ART regimen selection. They found no significant difference in virological failure between the 
OLA-guided therapy arm (8.5%) and the standard of care arm (9.7%) after 12 months on ART. 
Amongst the 9.4% of individuals with PDR, as defined by the presence of pre-specified OLA-
detected mutations, virologic failure was lower in the OLA-guided therapy arm (14%) than the SOC 
arm (50%). Nonetheless, PDR testing was not found to be beneficial in the overall cohort. A few 
limitations include the open-label nature of the study and lack of evaluation of the clinical impact of 
other nucleoside reverse transcriptase inhibitor PDR except the M184V. For example, the presence of 
the H208Y and T215Y mutations may lead to hyper-susceptibility to NNRTIs4   
There were two main reasons why pre-treatment resistance testing did not appear to demonstrate 
improvements in virologic outcomes in this study. First, although HIV drug resistance reduces 
treatment efficacy, this study reinforces that it by no means abrogates it. Approximately 48% of 
individuals in the SOC arm with PDR (2% cut-off) achieved virologic suppression at 12 months. 
Second, PDR was not significantly common to make testing for it to improve outcomes on a 
population level. Indeed, these results highlight that, unless PDR is exceptionally common, testing for 
it is unlikely to significantly impact care (Table). 
This study will not resolve the ongoing debates about selection of optimal first-line ART regimens in 
areas with a high prevalence of circulating resistance. It does add to a growing number of studies 
demonstrating high efficacy with EFV-based ART in such areas. The findings from this study is 
similar to another in rural South Africa, with high virological suppression (95%), despite the presence 
of NNRTI PDR (8.8%)5. Similarly, in the ADVANCE study, EFV achieved similar suppression rates 
as dolutegravir as first-line ART, without pre-therapy resistance testing, and notably achieved >95% 
in the per-protocol analysis6.  These data stand in contrast to modelling studies, which generally apply 
lower virologic suppression rates with EFV in the face of NNRTI resistance, and partly informed the 
WHO guidelines7,8. 
In summary, this well-designed randomized study by Chung et al, provides a significant advance for 
the field by helping to clarify the limited role for PDR testing at the population level in low-resource 
settings, even in areas with high prevalence of circulating drug resistance. It also adds important data 
to the debate about optimal first-line regimens in resource-limited settings where programmatic 
guidelines and relatively limited treatment options drive the vast majority of regimen decision 
making. Although beyond the scope of this review, additional data on the possible side effects and 
toxicity of dolutegravir, including neural tube defects9 and weight gain6, add to the complexity around 
the optimal choice of first-line regimens in the region. Thus, while dolutegravir maintains many 
advantages over efavirenz in terms of potency, costs of generic production, and side effect profiles10 
its advantage in terms of management in individuals with drug resistance remains to be fully clarified.   
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Table.  Case base scenario for number needed to treat for 12 months according to pre-treatment drug 
resistance (PDR) prevalence observed in OLA (0.0975) and SOC (0.0769) arms in Chung et al. and 
simulations at different levels of PDR prevalence 
 OLA arm Standard of care arm  
Case base PDR prevalence 
0.0975 
 PDR prevalence 
0.0769 
  
 N Virologic 
failure 
(VF) 
Probability 
of VF 
N VF Probability 
of VF 
Absolute diff. 
in prob. of VF 
NNT 
Total 400 34 0.08500 403 39 0.09677 0.01177 84.9 
Wild type 361 28 0.07756 372 24 0.06452   
2-9% 4 1 0.25000 5 2 0.40000   
10%+ 35 5 0.14286 26 13 0.50000   
PDR 39 6 0.15385 31 15 0.48387   
Simulations PDR prevalence  PDR prevalence   
 0.10 0.08519 0.10 0.10645 0.02126 47.0 
 0.15 0.08900 0.15 0.12741 0.03841 26.0 
 0.20 0.09281 0.20 0.14839 0.05558 18.0 
 0.25 0.09663 0.25 0.16935 0.07272 13.8 
 0.30 0.10044 0.30 0.19032 0.08988 11.1 
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